Deciphera rakes in over $90 mln
Waltham, Massachusetts-based Deciphera Pharmaceuticals, an biotechnology company focused on developing advanced kinase inhibitor treatments, has raised over $90 million in Series B funding. The company's newest investor is SV Life Sciences. In addition to the investment, Dr. Michael Ross, a managing partner at SV Life Sciences, has been added to Deciphera's board of directors.
5 January 2016•3 mins read
